Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Innovation Pharmaceuticals's Enterprise Value for the quarter that ended in Sep. 2023 was $5.59 Mil.
Innovation Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovation Pharmaceuticals EV-to-EBIT Related Terms
Innovation Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovation Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovation Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovation Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Innovation Pharmaceuticals's EV-to-EBIT falls into.
Innovation Pharmaceuticals's current Enterprise Value is $-0.21 Mil.
Innovation Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovation Pharmaceuticals (IPIX) has a EV-to-EBIT of 0.08 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' EV-to-EBIT too high?
Innovation Pharmaceuticals' current EV-to-EBIT is 0.08. The Biotechnology industry median EV-to-EBIT is 13.26. Innovation Pharmaceuticals' value of 0.08 is 99.4% below this industry median.
How does Innovation Pharmaceuticals' EV-to-EBIT compare to AXIM and RNAZ?
Innovation Pharmaceuticals' EV-to-EBIT of 0.08 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 13.26. Innovation Pharmaceuticals' value of 0.08 is 99.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.26, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovation Pharmaceuticals's current EV-to-EBIT of 0.08 is 99.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Innovation Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovation Pharmaceuticals's current EV-to-EBIT is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current EV-to-EBIT of 0.08. The current EV-to-EBIT is 0.08 and 99.4% below the Biotechnology industry median of 13.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current EV-to-EBIT is 0.08 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IPIX has been successfully added to your 
